Stacy Morrow, MS, RN, PHR’s Post

The CARE Plan pilot will promote research and development of new rare disease drugs to address urgent unmet clinical needs in China, and offers the opportunity to involve Chinese patients in rare disease product development. It’s a valuable opportunity for local and foreign companies to have increased interactions with and input from the CDE during the development of their rare disease drugs. Find out more from my colleague Mingping Zhang, in our latest Regulatory Navigator blog.

The CARE Plan pilot will promote research and development of new rare disease drugs to address urgent unmet clinical needs in China, and offers the opportunity to involve Chinese patients in rare disease product development. It’s a valuable opportunity for local and foreign companies to have increased interactions with and input from the CDE during the development of their rare disease drugs. Find out more from my colleague Mingping Zhang, in our latest Regulatory Navigator blog.

The CARE Plan pilot will promote research and development of new rare disease drugs to address urgent unmet clinical needs in China, and offers the opportunity to involve Chinese patients in rare disease product development. It’s a valuable opportunity for local and foreign companies to have increased interactions with and input from the CDE during the development of their rare disease drugs. Find out more from my colleague Mingping Zhang, in our latest Regulatory Navigator blog.

The CARE Plan pilot will promote research and development of new rare disease drugs to address urgent unmet clinical needs in China, and offers the opportunity to involve Chinese patients in rare disease product development. It’s a valuable opportunity for local and foreign companies to have increased interactions with and input from the CDE during the development of their rare disease drugs. Find out more from my colleague Mingping Zhang, in our latest Regulatory Navigator blog.

The CARE Plan pilot will promote research and development of new rare disease drugs to address urgent unmet clinical needs in China, and offers the opportunity to involve Chinese patients in rare disease product development. It’s a valuable opportunity for local and foreign companies to have increased interactions with and input from the CDE during the development of their rare disease drugs. Find out more from my colleague Mingping Zhang, in our latest Regulatory Navigator blog.

The CARE Plan pilot will promote research and development of new rare disease drugs to address urgent unmet clinical needs in China, and offers the opportunity to involve Chinese patients in rare disease product development. It’s a valuable opportunity for local and foreign companies to have increased interactions with and input from the CDE during the development of their rare disease drugs. Find out more from my colleague Mingping Zhang, in our latest Regulatory Navigator blog.

The CARE Plan pilot will promote research and development of new rare disease drugs to address urgent unmet clinical needs in China, and offers the opportunity to involve Chinese patients in rare disease product development. It’s a valuable opportunity for local and foreign companies to have increased interactions with and input from the CDE during the development of their rare disease drugs. Find out more from my colleague Mingping Zhang, in our latest Regulatory Navigator blog.

The CARE Plan pilot will promote research and development of new rare disease drugs to address urgent unmet clinical needs in China, and offers the opportunity to involve Chinese patients in rare disease product development. It’s a valuable opportunity for local and foreign companies to have increased interactions with and input from the CDE during the development of their rare disease drugs. Find out more from my colleague Mingping Zhang, in our latest Regulatory Navigator blog.

The CARE Plan pilot will promote research and development of new rare disease drugs to address urgent unmet clinical needs in China, and offers the opportunity to involve Chinese patients in rare disease product development. It’s a valuable opportunity for local and foreign companies to have increased interactions with and input from the CDE during the development of their rare disease drugs. Find out more from my colleague Mingping Zhang, in our latest Regulatory Navigator blog.

Just about a week to go and counting! I am excited to see everyone in San Diego at #DIA2024. What a treat to discuss "Sustainability of Rare Disease Drug Development" with an esteemed panel of FDA experts including Julie Tierney, Patroula Smpokou, MD, and Katherine Donigan - of course expertly moderated by Darcy Frear, PhD. Current incentives for #raredisease #drugdevelopment including the #orphandrugact #ODA have changed to world for many #raredisease patients and families. We went from fewer than 40 FDA approved therapies in 1983 before the #ODA to #orphandrugs consistently making up more than 50% of new drug approvals (#NMEs) at #FDA. But more than 95% of rare diseases still lack any FDA-approved therapies. So how do we sustainably improve rare disease drug development and bring life-changing therapies to those communities that have for too long been left behind? There are so many promising approaches, pilots, and policy priorities to make this dream a reality, and I can't wait to discuss them with this esteemed panel of experts!